WHO 2010 and WHO 2000 Classification: From a Sensitive Analysis to Reality

Claudio Ricci\textsuperscript{1}, Francesco Monari\textsuperscript{1}, Salvatore Buscemi\textsuperscript{1}, Mariella D’Ambra\textsuperscript{1}, Davide Campana\textsuperscript{2}, Riccardo Panzacchi\textsuperscript{3}, Claudio Ceccarelli\textsuperscript{3}, Marcello Labombarda\textsuperscript{1}, Giovanni Taffurelli\textsuperscript{1}, Raffaele Pezzilli\textsuperscript{2}, Donatella Santini\textsuperscript{3}, Paola Tomassetti\textsuperscript{2}, Riccardo Casadei\textsuperscript{1}, Francesco Minni\textsuperscript{1}

Departments of \textsuperscript{1}Surgery, \textsuperscript{2}Internal Medicine and Gastroenterology and \textsuperscript{3}Pathology, “S.Orsola-Malpighi” Hospital. Bologna, Italy

Context In 2010 WHO released a new classification system for pancreatic endocrine tumors (PETs). Objectives To compare WHO-2010 with WHO-2000 classification in patients affected by PETs who underwent surgery. Methods Data regarding 67 patients were extracted from a dedicate database containing 92 patients undergone surgical exploration for pancreatic neuroendocrine tumors (pNETs). Patients without Ki-67 determination were excluded. Sex, age, presence of symptoms, hormonal status, site of tumor, presence of MEN1, surgical procedure, R status, TNM-ENETS stage, WHO 2000 and WHO 2010 classification, Ki-67, disease specific survival (DSS) with univariate and multivariate analyses. Results There were 36 (53.7\%) females and 31 (46.3\%) males. Mean age of patients was 57±13 years. Symptoms were present in 49 (73.1\%) patients. Forty-nine (73.1\%) patients had non-functioning pNETs and the tumour was located more frequently in the head (34.3\%) and body (37.3\%). Seven (10.4\%) patients were affected by MEN1. R0 resection was carried out in 54 cases (80.6\%) cases. Ki-67 was <2\% in 30 (44.8\%) patients, ranged 2-20\% in 33 (49.3\%) patients and was >20\% in 4 (6.0\%) patients. According WHO-2000, 33 (49.3\%) patients had a well differentiated tumours (WDT), 26 (38.8\%) had well differentiated carcinoma (WDCa), and 8 (11.9\%) had poorly differentiated carcinoma (PDCa). According to WHO 2010, 30 (44.8\%) pNETs G1, 33 (49.3\%) pNETs G2 and 4 (6.0\%) pancreatic neuroendocrine carcinomas (pNECs) G3. According TNM-ENETS stage there were 28 (41.8\%), 4 (6.0\%), 24 (35.8\%) and 11 (16.4\%) patients in stage I, II, III, and IV, respectively. Mean DSS was 263±17 months. Multivariate analysis found that WHO 2000 was the only independent factor related to DSS (HR=24; P=0.003). Conclusion WHO 2000 remains in our experience the best factor predicting DSS in patient affected by pNETs.